FDA approves Regeneron drug for macular edema

TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.

"This second U.S. approval for Eylea provides physicians and patients with a new treatment option for the treatment of macular edema following CRVO," Regeneron chief scientific officer and Regeneron Labs president George Yancopoulos said.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.